

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | | |
|----|--|
| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|----|--|

No equality issues were identified, but Myeloma UK commented:

- | |
|--|
| <ul style="list-style-type: none">• As with all treatments the costs incurred by hospital visits and time off work will have a more significant impact on people with lower incomes. |
|--|

- | | |
|----|--|
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|----|--|

There are no potential equality issues that are within the remit of the committee to address.

- | | |
|----|---|
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
|----|---|

No.

- | | |
|----|---|
| 4. | Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made? |
|----|---|

Technology appraisals: Scoping

Equality impact assessment for the proposed single technology appraisal of daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]

Issue date: May 2025

No.

Approved by Associate Director (name):Richard Diaz.....

Date: ...29 April 2025.....